Nascent Biotechinc Otcmkts Nbiois A Public Companyformed In March 2014To Continue Development Of Pritumumaba Human Monoclonal Antibody Created By A Number Of Leading Scientists Who Have Developed Various Monoclonal Antibodies And Cytokine Treatments For Oncology Indications Pritumumab Recognizes A Unique And Proprietary Antigen Expressed On The Surface Of Cancer Cells And Is Being Developed To Treat Brain And Pancreatic Cancersboth Unmet Clinical Needs Nbio S Clinical Premise Is That The Most Effective Way To Treat Disease Is To Modulateboost Or Suppressthe Human Body S Natural Ability To Generate An Immune Response Often Referred To Asimmunotherapy The Scientific Approach Is Based Upon Two Discrete Types Of Regulatory Moleculesmonoclonal Antibodies And Cytokines That Can Be Combined To Maximize Therapeutic Effectiveness In A Variety Of Diseases Monoclonal Antibodiesmabsare Naturally Occurring Proteins That Bind With Exquisite Specificity To Molecular Structures On The Surface Of Target Cells Monoclonal Antibodies Arecollectivelythe Fastest Growing Products In The Entire Pharmaceutical Industry In 2005No Mabs Were Among The Top 10 Selling Drugs In The World By 2010They Were 5 Of The Top 10 Selling Drugsaccounting For $34 1 Billion In Annual Sales And 45Of Total Sales Of The Top 10 By 20136 Of The Top 10 Selling Drugs Worldwide Were Mabs Accounting For $50 1 Billion In Sales Ae66Of Top 10 Total Sales Worldwide
No conferences found for this company.
| Company Name | Nascent Biotech Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
